Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Downgraded by Wall Street Zen to "Hold"

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Friday.

A number of other equities research analysts also recently weighed in on BAYRY. Kepler Capital Markets upgraded Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report on Wednesday, June 11th. Hsbc Global Res raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, June 11th. Finally, The Goldman Sachs Group upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Bayer Aktiengesellschaft presently has a consensus rating of "Buy".

Bayer Aktiengesellschaft Price Performance

Shares of BAYRY traded down $0.09 during trading hours on Friday, hitting $7.68. The stock had a trading volume of 905,778 shares, compared to its average volume of 804,136. The stock has a market capitalization of $30.18 billion, a price-to-earnings ratio of -8.35 and a beta of 0.85. The company's fifty day moving average is $6.85 and its two-hundred day moving average is $6.03. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.25 and a quick ratio of 0.79. Bayer Aktiengesellschaft has a 52 week low of $4.79 and a 52 week high of $8.58.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported $0.65 earnings per share for the quarter, beating analysts' consensus estimates of $0.63 by $0.02. The firm had revenue of $15.27 billion during the quarter, compared to analysts' expectations of $13.39 billion. Bayer Aktiengesellschaft had a positive return on equity of 13.94% and a negative net margin of 7.26%. On average, analysts anticipate that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.